Nature,
Год журнала:
2019,
Номер
569(7758), С. 641 - 648
Опубликована: Май 29, 2019
Abstract
The
NIH
Human
Microbiome
Project
(HMP)
has
been
carried
out
over
ten
years
and
two
phases
to
provide
resources,
methods,
discoveries
that
link
interactions
between
humans
their
microbiomes
health-related
outcomes.
recently
completed
second
phase,
the
Integrative
Project,
comprised
studies
of
dynamic
changes
in
microbiome
host
under
three
conditions:
pregnancy
preterm
birth;
inflammatory
bowel
diseases;
stressors
affect
individuals
with
prediabetes.
associated
research
begins
elucidate
mechanisms
host–microbiome
these
conditions,
provides
unique
data
resources
(at
HMP
Data
Coordination
Center),
represents
a
paradigm
for
future
multi-omic
human
microbiome.
Cell Research,
Год журнала:
2020,
Номер
30(6), С. 492 - 506
Опубликована: Май 20, 2020
Abstract
The
interplay
between
the
commensal
microbiota
and
mammalian
immune
system
development
function
includes
multifold
interactions
in
homeostasis
disease.
microbiome
plays
critical
roles
training
of
major
components
host’s
innate
adaptive
system,
while
orchestrates
maintenance
key
features
host-microbe
symbiosis.
In
a
genetically
susceptible
host,
imbalances
microbiota-immunity
under
defined
environmental
contexts
are
believed
to
contribute
pathogenesis
multitude
immune-mediated
disorders.
Here,
we
review
microbiome-immunity
crosstalk
their
health
disease,
providing
examples
molecular
mechanisms
orchestrating
these
intestine
extra-intestinal
organs.
We
highlight
aspects
current
knowledge,
challenges
limitations
achieving
causal
understanding
host
immune-microbiome
interactions,
as
well
impact
on
diseases,
discuss
how
insights
may
translate
towards
future
microbiome-targeted
therapeutic
interventions.
Science,
Год журнала:
2018,
Номер
359(6371), С. 104 - 108
Опубликована: Янв. 5, 2018
Anti-PD-1-based
immunotherapy
has
had
a
major
impact
on
cancer
treatment
but
only
benefited
subset
of
patients.
Among
the
variables
that
could
contribute
to
interpatient
heterogeneity
is
differential
composition
patients'
microbiome,
which
been
shown
affect
antitumor
immunity
and
efficacy
in
preclinical
mouse
models.
We
analyzed
baseline
stool
samples
from
metastatic
melanoma
patients
before
treatment,
through
an
integration
16
Annals of Oncology,
Год журнала:
2018,
Номер
30(1), С. 44 - 56
Опубликована: Ноя. 1, 2018
Treatment
with
immune
checkpoint
blockade
(ICB)
agents
such
as
anti-programmed
cell
death
protein
1
(PD-1),
death-ligand
(PD-L1),
and/or
anti-cytotoxic
T-lymphocyte-associated
4
(CTLA-4)
can
result
in
impressive
response
rates
and
durable
disease
remission
but
only
a
subset
of
patients
cancer.
Expression
PD-L1
has
demonstrated
utility
selecting
for
to
ICB
proven
be
an
important
biomarker
patient
selection.
Tumor
mutation
burden
(TMB)
is
emerging
potential
biomarker.
However,
refinement
interpretation
contextualization
required.
